Skip to content
Disclosery

Frazier Life Sciences Management, L.P.

Follow

13F filer, CIK 1892134, PALO ALTO, CA

Frazier Life Sciences Management, L.P. reported $4,592,076,814 across 41 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 73.61% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001892134-26-000003

Period
2026-06-30
Reported value
$4.59B
Holdings
41
Top 10 weight
73.61%
New
6
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
PBLSnew+1,920,805$52.6M
ACHVnew+7,614,836$49.7M
NAMSadded+1,145,128$38.8M
ALLOadded+18,650,000$38.8M
DSGNnew+1,809,854$26.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
BBIOreduced-1,900,000-$142M
KALVexited-4,961,108-$99.9M
RVMDexited-675,686-$65.7M
AGIOexited-1,256,080-$42.5M
TRVIreduced-100-$1.86K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001892134-26-000003, largest first. % of portfolio is the value over $4,592,076,814, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 6,570,392 shares; 2024Q4: 6,570,392 shares; 2025Q1: 6,795,121 shares; 2025Q2: 6,795,121 shares; 2025Q3: 6,795,121 shares; 2025Q4: 6,795,121 shares; 2026Q1: 7,679,684 shares; 2026Q2: 7,679,684 shares 7,679,684$899M19.58%0Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 12,855,194 shares; 2024Q4: 15,916,418 shares; 2025Q1: 16,116,418 shares; 2025Q2: 16,607,074 shares; 2025Q3: 16,701,956 shares; 2025Q4: 16,943,774 shares; 2026Q1: 16,943,774 shares; 2026Q2: 18,088,902 shares 18,088,902$613M13.35%+1,145,128Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 19,391,687 shares; 2024Q4: 19,391,687 shares; 2025Q1: 22,575,851 shares; 2025Q2: 22,729,436 shares; 2025Q3: 22,729,436 shares; 2025Q4: 22,729,436 shares; 2026Q1: 24,675,188 shares; 2026Q2: 24,975,188 shares 24,975,188$458M9.96%+300,000Timeline
MBXMBX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 5,985,347 shares; 2024Q4: 5,985,347 shares; 2025Q1: 5,985,347 shares; 2025Q2: 5,985,347 shares; 2025Q3: 6,652,013 shares; 2025Q4: 6,652,013 shares; 2026Q1: 6,652,013 shares; 2026Q2: 6,652,013 shares 6,652,013$367M8%0Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,785,284 shares; 2024Q4: 8,785,284 shares; 2025Q1: 8,785,284 shares; 2025Q2: 9,874,511 shares; 2025Q3: 9,874,511 shares; 2025Q4: 9,874,511 shares; 2026Q1: 9,874,511 shares; 2026Q2: 9,874,511 shares 9,874,511$259M5.64%0Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 7,381,090 shares; 2024Q4: 10,664,774 shares; 2025Q1: 10,259,409 shares; 2025Q2: 10,259,409 shares; 2025Q3: 10,259,409 shares; 2025Q4: 10,259,409 shares; 2026Q1: 9,939,547 shares; 2026Q2: 9,939,447 shares 9,939,447$185M4.04%-100Timeline
KRYSKRYSTAL BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 988,460 shares; 2024Q4: 788,460 shares; 2025Q1: 688,460 shares; 2025Q2: 688,460 shares; 2025Q3: 688,460 shares; 2025Q4: 488,460 shares; 2026Q1: 481,307 shares; 2026Q2: 481,307 shares 481,307$179M3.9%0Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 4,129,001 shares; 2025Q2: 4,567,275 shares; 2025Q3: 4,567,274 shares; 2025Q4: 4,567,274 shares; 2026Q1: 4,567,274 shares; 2026Q2: 5,032,915 shares 5,032,915$150M3.27%+465,641Timeline
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 10,109,279 shares; 2024Q4: 10,109,279 shares; 2025Q1: 10,109,279 shares; 2025Q2: 12,466,489 shares; 2025Q3: 12,466,489 shares; 2025Q4: 12,466,489 shares; 2026Q1: 12,466,489 shares; 2026Q2: 12,466,489 shares 12,466,489$135M2.95%0Timeline
PVLAPALVELLA THERAPEUTICS INC NEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 653,892 shares; 2025Q1: 690,012 shares; 2025Q2: 722,400 shares; 2025Q3: 722,400 shares; 2025Q4: 722,400 shares; 2026Q1: 882,400 shares; 2026Q2: 882,400 shares 882,400$135M2.94%0Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,760,457 shares; 2024Q4: 3,800,457 shares; 2025Q1: 3,800,457 shares; 2025Q2: 3,800,457 shares; 2025Q3: 3,845,457 shares; 2025Q4: 3,545,557 shares; 2026Q1: 3,448,139 shares; 2026Q2: 1,548,139 shares 1,548,139$115M2.51%-1,900,000Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,754,834 shares; 2024Q4: 1,754,834 shares; 2025Q1: 1,754,834 shares; 2025Q2: 1,654,834 shares; 2025Q3: 1,438,534 shares; 2025Q4: 1,260,000 shares; 2026Q1: 1,354,852 shares; 2026Q2: 1,354,852 shares 1,354,852$99.1M2.16%0Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 554,731 shares; 2025Q3: 890,445 shares; 2025Q4: 934,642 shares; 2026Q1: 1,159,879 shares; 2026Q2: 1,159,879 shares 1,159,879$98.8M2.15%0Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,443,341 shares; 2025Q2: 1,505,984 shares; 2025Q3: 2,718,105 shares; 2025Q4: 3,153,082 shares; 2026Q1: 3,153,082 shares; 2026Q2: 3,153,082 shares 3,153,082$70M1.53%0Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 133,333 shares; 2024Q4: 133,333 shares; 2025Q1: 133,333 shares; 2025Q2: 133,333 shares; 2025Q3: 133,333 shares; 2025Q4: 133,333 shares; 2026Q1: 133,333 shares; 2026Q2: 225,155 shares 225,155$60.1M1.31%+91,822Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,157,385 shares; 2024Q4: 8,660,379 shares; 2025Q1: 11,462,301 shares; 2025Q2: 11,462,301 shares; 2025Q3: 11,462,301 shares; 2025Q4: 9,862,301 shares; 2026Q1: 9,720,852 shares; 2026Q2: 9,720,852 shares 9,720,852$59.9M1.3%0Timeline
PBLSPARABILIS MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,920,805 shares 1,920,805$52.6M1.14%newTimeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 5,100,000 shares; 2025Q3: 5,100,000 shares; 2025Q4: 5,100,000 shares; 2026Q1: 5,100,000 shares; 2026Q2: 7,100,000 shares 7,100,000$50.4M1.1%+2,000,000Timeline
ACHVACHIEVE LIFE SCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 7,614,836 shares 7,614,836$49.7M1.08%newTimeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,543,939 shares; 2026Q1: 2,543,939 shares; 2026Q2: 2,543,939 shares 2,543,939$46.8M1.02%0Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,867,750 shares; 2024Q4: 2,867,750 shares; 2025Q1: 3,868,750 shares; 2025Q2: 3,868,750 shares; 2025Q3: 3,868,750 shares; 2025Q4: 3,868,750 shares; 2026Q1: 3,796,668 shares; 2026Q2: 22,446,668 shares 22,446,668$46.7M1.02%+18,650,000Timeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,587,527 shares; 2024Q4: 1,587,527 shares; 2025Q1: 1,397,527 shares; 2025Q2: 1,397,527 shares; 2025Q3: 1,167,527 shares; 2025Q4: 728,644 shares; 2026Q1: 728,644 shares; 2026Q2: 728,644 shares 728,644$45.9M1%0Timeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 4,009,240 shares; 2026Q2: 4,009,240 shares 4,009,240$40.1M0.87%0Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 576,129 shares; 2024Q4: 601,129 shares; 2025Q1: 601,129 shares; 2025Q2: 1,000,647 shares; 2025Q3: 700,647 shares; 2025Q4: 700,647 shares; 2026Q1: 700,647 shares; 2026Q2: 700,647 shares 700,647$36.7M0.8%0Timeline
ACADACADIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 470,338 shares; 2024Q4: 470,338 shares; 2025Q1: 470,338 shares; 2025Q2: not reported; 2025Q3: 613,837 shares; 2025Q4: 1,297,198 shares; 2026Q1: 1,438,198 shares; 2026Q2: 1,438,198 shares 1,438,198$36.4M0.79%0Timeline
ZLABZAI LAB LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 350,000 shares; 2025Q2: 1,308,138 shares; 2025Q3: 1,627,320 shares; 2025Q4: 1,902,320 shares; 2026Q1: 1,902,320 shares; 2026Q2: 1,902,320 shares 1,902,320$36.1M0.79%0Timeline
MNKDMANNKIND CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 4,225,000 shares; 2026Q1: 5,900,000 shares; 2026Q2: 6,600,000 shares 6,600,000$28.1M0.61%+700,000Timeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,892,547 shares; 2024Q4: 1,953,547 shares; 2025Q1: 1,953,547 shares; 2025Q2: 1,953,547 shares; 2025Q3: 1,953,547 shares; 2025Q4: 521,000 shares; 2026Q1: not reported; 2026Q2: 1,809,854 shares 1,809,854$26.2M0.57%newTimeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 264,377 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 4,925,374 shares; 2026Q2: 4,925,374 shares 4,925,374$26.1M0.57%0Timeline
STTKSHATTUCK LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,750,000 shares 3,750,000$26M0.57%newTimeline
KLRAKAILERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,100,000 shares 1,100,000$24.2M0.53%newTimeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,000,000 shares; 2026Q2: 1,000,000 shares 1,000,000$24.2M0.53%0Timeline
LXEOLEXEO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,250,786 shares; 2024Q4: 955,515 shares; 2025Q1: 955,515 shares; 2025Q2: 4,424,725 shares; 2025Q3: 4,424,725 shares; 2025Q4: 4,424,725 shares; 2026Q1: 4,424,725 shares; 2026Q2: 4,824,725 shares 4,824,725$22.5M0.49%+400,000Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,015,693 shares 1,015,693$19M0.41%newTimeline
EOLSEVOLUS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 2,435,550 shares; 2025Q3: 2,630,665 shares; 2025Q4: 2,630,665 shares; 2026Q1: 2,630,665 shares; 2026Q2: 2,630,665 shares 2,630,665$18.3M0.4%0Timeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 108,762 shares; 2024Q4: 108,762 shares; 2025Q1: 301,170 shares; 2025Q2: 384,782 shares; 2025Q3: 384,782 shares; 2025Q4: 384,782 shares; 2026Q1: 484,782 shares; 2026Q2: 484,782 shares 484,782$15.4M0.34%0Timeline
VALNVALNEVA SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,458,333 shares; 2025Q3: 2,291,666 shares; 2025Q4: 2,291,666 shares; 2026Q1: 2,291,666 shares; 2026Q2: 2,291,666 shares 2,291,666$12M0.26%0Timeline
NEWAMSTERDAM PHARMA COMPANYNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 500,333 shares; 2024Q4: 500,333 shares; 2025Q1: 500,333 shares; 2025Q2: 500,333 shares; 2025Q3: 500,333 shares; 2025Q4: 500,333 shares; 2026Q1: 500,333 shares; 2026Q2: 500,333 shares 500,333$10.7M0.23%0
AUTLAUTOLUS THERAPEUTICS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 4,623,324 shares; 2024Q4: 4,623,324 shares; 2025Q1: 4,623,324 shares; 2025Q2: 4,623,324 shares; 2025Q3: 4,623,324 shares; 2025Q4: 4,623,324 shares; 2026Q1: 4,447,910 shares; 2026Q2: 4,447,910 shares 4,447,910$7.12M0.15%0Timeline
XLOXILIO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 422,505 shares; 2026Q2: 422,505 shares 422,505$4.05M0.09%0Timeline
IBIOIBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,953,467 shares; 2026Q1: 1,953,467 shares; 2026Q2: 1,953,467 shares 1,953,467$3.42M0.07%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
KALVKALVISTA PHARMACEUTICALS INC4,961,108$99.9Mshares
RVMDREVOLUTION MEDICINES INC675,686$65.7Mshares
AGIOAGIOS PHARMACEUTICALS INC1,256,080$42.5Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001892134-26-000003 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001892134-26-000003 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001892134-26-000002 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001892134-26-000001 Quarter ended 2025-12-312026-02-13acceptance time not in the bulk data set
13F-HR 0001892134-25-000012 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001892134-25-000006 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001892134-25-000005 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001892134-25-000001 Quarter ended 2024-12-312025-02-18acceptance time not in the bulk data set
13F-HR 0001892134-24-000006 Quarter ended 2024-09-302024-11-15acceptance time not in the bulk data set
13F-HR 0001892134-24-000004 Quarter ended 2024-06-302024-08-15acceptance time not in the bulk data set
13F-HR 0001892134-24-000003 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0001892134-24-000002 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001892134-23-000001 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0001420506-23-001580 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0001420506-23-001125 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR/A 0001420506-23-000277 Quarter ended 2022-12-312023-02-07acceptance time not in the bulk data set
13F-HR 0001420506-23-000230 Quarter ended 2022-12-312023-02-03acceptance time not in the bulk data set
13F-HR 0001420506-22-002171 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0001420506-22-001455 Quarter ended 2022-06-302022-08-10acceptance time not in the bulk data set
13F-HR 0001420506-22-000953 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set